Search

Your search keyword '"Mai Huyen Thi Thu"' showing total 2 results
Start Over Author "Mai Huyen Thi Thu"
2 results on '"Mai Huyen Thi Thu"'

1. Natural Occurrence, Morpho‐Molecular Characteristics, and Pathogenicity of Fusarium spp. Associated With Chrysanthemum Wilt in Vietnam.

Author

Le, Dung, Ta, Tam Thi Thanh, Nguyen, Phuong Van, and Mai, Huyen Thi Thu

Subjects
SPRINKLER irrigation, FUSARIUM oxysporum, STUNTED growth, DISEASE incidence, CHRYSANTHEMUMS
Abstract

Chrysanthemum Fusarium wilt (CFW) is a devastating soil‐borne disease affecting the cut chrysanthemum industry globally. In Vietnam, this disease has been occurring silently and is posing a risk of epidemic outbreaks in the southern provinces, especially Lam Dong. Results from a survey in 2023 showed that stunted growth, curved and small stems, dried‐rot roots, leaf drooping and green or yellow wilting of plants after transplanting or at their flower bud initiation were common symptoms observed across the main chrysanthemum‐growing farms in Lam Dong. The occurrence of CFW was recorded in relation with the host cultivar, irrigation method and fungicide‐spraying regime. Among the cultivars grown in Lam Dong, 'Doa cu' was the most susceptible to CFW. The use of sprinkler irrigation and infrequent application of fungicides were attributed to increase both disease incidence and severity. Thirty fungal isolates obtained from diseased plants were identified as Fusarium oxysporum and F. falciforme based on morphological features and molecular analysis of ITS and TEF‐1α genes. The detection frequency of these two species was almost equal, which shows their balanced role in the occurrence of CFW in Lam Dong. In‐planta pathogenicity assays of Fusarium isolates against plantlets grown from cuttings and invitro propagation showed a variation in pathogenicity and a specialisation of isolates for these planting materials. These results suggest that the profiles of population and aggressiveness of Fusarium isolates diverged with the type of planting material, and between the stock and the commercial farms. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

2. Lancet Infect Dis

Author

Valdilea G. Veloso, Domergue Anaïs, De Solère Marie, Do cha Giang, Le Thi Ngoc bich, Timana Isabel, Mai Thu Huyen Nguyet, Nguyen Nuoi Thi, Nilesh Bhatt, Nguyen Cao van thi, Amani Jacqueline, Serge Eholié, Isabel Timana Massango, Kan Samuel, Moreira Ronaldo ismerio, Beuscart Aurélie, Siloue Yamissa, Siloue Bertine, Dano Lehi Florence, Azam Khalide, Koné Fatoumata, Khosa Celso, Da Silva Robson Pierre, Nazer Sandro, Huynh Anh Phuong, Chazallon Corine, Sandra W. Cardoso, Previllon Miresta, Santana de Moura Soraia, Aka Kakou, Lessa Flávia, Tran Thi Hieu Nhi, Tran Thi-Hai Ly, Mai Huyen Thi Thu, Barreto Débora Faber, Celso Khosa, Jean-Baptiste N'takpe, Molina Jean-michel, Tran Quy Thi Kim, Krsitic Tânia, Fanny Salimata, Montoyo Alice, Nguyen thi Hong, Anais Domergue, Tran Tien Thi Thuy, Grinsztejn Beatriz, Camacho Luiz, Kacou Jean-claude, Gonzales Maura lassance, Tavora dos Santos Filho Ezio, Corine Chazallon, Ahyi Irmine, Nguyen duc Bang, Laureillard Didier, Guiroy Frederique, Luong Anh Que, Vu Xuan Thinh, Tran Ton, Didier Laureillard, Dinh phuong Thanh, Dang thi Minh Há, Gomes Tatiane, Menan Hervé, Bastos dos Santos Rui, Rapoud Delphine, Anzian Amani, De castro Nathalie, Eholie Serge, Pham Anh Thi Quynh, Amoakon Bonzou, Konan Lambert, Coelho Lara, Matsinhe Lectícia, Xavier Anglaret, Rodrigo Escada, Ha Thanh Trang Do, Ponscarme Diane, Gbey Robert, Dong bui vu hoang Trang Quynh Nhu, Konan Romuald, Beatriz Grinsztejn, Eugène Messou, Nguyen ngoc Lan, Cao Tung khanh, Bonnet Maryline, Nathalie De Castro, Etilé Etienne, Taburet Anne-marie, Tavares Isabel cristina, Torres Thiago, Nguyen nhu Viet, Kouamé Martin, Rebelo Daniel, N'takpé Jean-baptiste, Emieme Arlette, Diomandé Donald, Veloso Valdilea, Kassy Mc, Manhiça Emelva, Tran Thao Pham Phuong, Karcher Sophie, Santos Desiree, Salgado Lucimar, Cong thi Mai Luong, Rekacewicz Claire, Pham Hang Thu, Tran Loc Huu, Bhatt Nilesh, Toni Thomas-d'aquin, Wagner Sandra, Marins Luana, Vubil Adolfo, Sitoe Nádia, Huynh hoang Khanh thu, Kouadio Suzanne, Jean-Michel Molina, Irié Marcelin, Olivier Marcy, Labibi Georgette, Tchehy Cecile, Nguyen huu Lân, Messou Eugène, Marcy Olivier, Rabe Cyprien, Escada Rodrigo, Anglaret Xavier, Ribeiro Jorge, Bui thi Kim Nhung, Alves Ana cláudia, Zitha Alcina, Giang Do Chau, Ribeiro Valéria rita, Eboumou Fulgence, Ello Frederick, Le Guoc Khanh, Long Van Duong, Delaugerre Constance, Bi Antoine, Hoagland Brenda, Gnokoro Joachim, Diallo Alpha, Constance Delaugerre, Do ha thanh Trang, Astrid, Ferreira Ana cristina, Vilanculo Arlindo, Nhumaio Dilário, Le Carrou Jérôme, Bordeaux population health (BPH), and Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Cyclopropanes, Male, 0301 basic medicine, HIV Infections, chemistry.chemical_compound, 0302 clinical medicine, Drug Dosage Calculations, 030212 general & internal medicine, Mozambique, Aged, 80 and over, education.field_of_study, Coinfection, virus diseases, Lamivudine, Middle Aged, 3. Good health, Treatment Outcome, Infectious Diseases, Vietnam, Alkynes, Female, France, Brazil, medicine.drug, Adult, medicine.medical_specialty, Efavirenz, Tuberculosis, Anti-HIV Agents, Population, Young Adult, 03 medical and health sciences, Acquired immunodeficiency syndrome (AIDS), Raltegravir Potassium, Internal medicine, medicine, Humans, education, Adverse effect, Aged, business.industry, medicine.disease, Raltegravir, 030112 virology, Benzoxazines, Cote d'Ivoire, chemistry, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, Rifampicin
Abstract

BACKGROUND: In patients co-infected with HIV and tuberculosis, antiretroviral therapy options are limited due to drug—drug interactions with rifampicin. A previous phase 2 trial indicated that raltegravir 400 mg twice a day or efavirenz 600 mg once a day might have similar virological efficacy in patients given rifampicin. In this phase 3 trial, we assessed the non-inferiority of raltegravir to efavirenz. METHODS: We did a multicentre, open-label, non-inferiority, randomised, phase 3 trial at six sites in Côte d'Ivoire, Brazil, France, Mozambique, and Vietnam. We included antiretroviral therapy (ART)-naive adults (aged ≥18 years) with confirmed HIV-1 infection and bacteriologically confirmed or clinically diagnosed tuberculosis who had initiated rifampicin-containing tuberculosis treatment within the past 8 weeks. Using computerised random numbers, we randomly assigned participants (1:1; stratified by country) to receive raltegravir 400 mg twice daily or efavirenz 600 mg once daily, both in combination with tenofovir and lamivudine. The primary outcome was the proportion of patients with virological suppression at week 48 (defined as plasma HIV RNA concentration

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results